BSX

Historical Earnings Track Record Around BSX

Boston Scientific has delivered a spotless beat record over its last eight reported quarters, hitting estimates on every single one for a 100% beat rate, and the average earnings surprise during that stretch sits at 5.5%. On the surface that suggests consistent operational performance, but price action has not rewarded that consistency in the short term. Across those same eight quarters the average 5-day price move in the five trading days after earnings is -4.73%, classified as a downward drift. This creates a counterintuitive picture: the company has beaten expectations every time while the stock, on average, has faded after the reports.

The last four quarters make that disconnect concrete. On April 22, 2026, Boston Scientific reported EPS of $0.80 versus an estimate of $0.788, a 1.5% beat, and the stock rose 1.26% the next day — then fell 11.9% over the following five trading days. On February 4, 2026, EPS of $0.80 beat the $0.781 estimate by 2.4%, the stock gained 2.83% the next session, and still drifted -2.69% over the next five days. The two reports before that were also beats: October 22, 2025, delivered $0.75 versus $0.714 (5% surprise) with an immediate -1.41% reaction and a -3.42% five-day drift; July 23, 2025, delivered $0.75 versus $0.725 (3.4% surprise) with a -1.44% next-day move and a -0.93% five-day drift. In all four instances the headline result topped the estimate, yet the window immediately after the report was dominated by selling pressure.

What the Next Earnings Date Means for Options and Flow

The next scheduled report is July 29, 2026, before the market open, with a consensus EPS estimate of $0.828. Because the historical beat rate is 100%, the unofficial consensus may already lean toward an inline or better result, which means the binary risk around the print is less about "beat or miss" and more about whether the report clears the higher bar the market's real expectation has set. Options activity into the event will likely reflect concern over volatility rather than direction: put/call skew, implied-volatility term structure, and the cost of straddles expiring just after July 29 can all indicate how much premium traders are paying for protection or speculation.

With the current price at $44.25, the 50-day EMA at $48.12, and RSI at 45.6, the setup into the report shows the stock already trading below a recently declining medium-term average and in neutral momentum territory. That backdrop can amplify how options market makers hedge around the print, since delta-hedging flows may accelerate moves in either direction depending on whether the stock opens above or below key short-delta strike concentrations. Traders watching flow should pay attention not just to whether the stock gaps up or down on the headline, but to whether dealers are positioned to be net buyers or sellers of underlying shares as they adjust hedges into the post-earnings move.

Tape Watchlist for a Disciplined Trader Around 2026-07-29

Given the -4.73% average five-day drift and the repeated pattern of post-beat selling, a disciplined approach around this report focuses on confirmation rather than anticipation. Specific checkpoints include: the direction and volume of the first 30 minutes after the open on July 29; whether the price holds above or breaks below the $44.25 pre-event level; and whether the immediate gap reverses or extends. Because the last three of the last four reports produced negative five-day returns, the historical base rate suggests that a beat alone has not been enough to sustain a rally.

Other inputs to watch include the stock's behavior relative to the $48.12 50-day EMA after any gap, and whether RSI moves toward oversold or overbought territory quickly enough to mean-reversion strategies. The Healthcare/Medical Devices sector can also move on broader reimbursement, regulatory, or tariff headlines that may overshadow the EPS figure, so cross-asset checks on sector ETFs and peers add useful context. For a deeper dive into how institutional analysts, options skew, and revenue and guidance expectations align with these price-based signals, readers should review the full institutional verdict.